GB Sciences Builds Broad Cannabis Patent Portfolio -- CFN Media
SEATTLE, WA--(NewMediaWire) - June 16, 2017 - - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article and interview with CEO John Poss, discussing GB Sciences Inc. (OTCQB: GBLX) and its drug development pipeline for novel cannabis-based therapies.
Researchers have only scratched the surface of the medical value of cannabinoids as federal regulations are relaxed. While GW Pharmaceuticals plc's epilepsy programs are well-known, cannabinoids could also play a role in mitigating or reversing the effects of neurological disorders, inflammatory diseases, and hundreds of other areas.
GB Sciences has several advantages over competitors ranging from its unique access to source materials to its efficient clinical discovery platform to its choice in patient populations.
The company began by selecting patient groups based on the current standard of care, the response of disease processes to cannabinoids, and the precedent for preclinical work needed to develop these therapies in FDA-sanctioned clinical trials. The goal is to develop therapeutics targeting patient groups that aren't being helped by other companies, while accelerating the time-to-market to deliver near-term shareholder value.
After identifying a patient population, the company's team of highly proficient scientists works to create a single elegant solution for the disease's problem set. The Network Pharmacology Platform and a high-throughput screening process helps to rapidly analyze thousands of potential combinations using cell-based models. This approach of working "smarter, not harder" helps keep costs low and maximizes the likelihood of success.
Finally, the company's licenses to grow, extract, and sell cannabis under state-regulated programs enables it to produce its own standardized raw materials for use in its R&D and clinical products. The company's R&D team has pioneered tissue-culture propagation techniques to reduce genetic drift in cannabis plants, while automated, controlled growing environments help standardize the production of active ingredients.
GB Sciences has filed three provisional patent applications containing formulations designed to tackle neurological disorders, inflammatory disorders, and chronic pain.
The company's first patent application covers cannabis-based complex mixtures designed to treat neurological disorders like Parkinson's disease, Lewy Body dementia, Huntington's disease, dementia, and Alzheimer's disease. The team believes that there is a common mechanism underlying these neurological disorders that its therapies address, which could prove invaluable as a growing number of patients require treatment.
The company's second patent application covers cannabis-based complex mixtures designed to treat inflammatory diseases, such as osteoarthritis, rheumatoid arthritis, Crohn's disease, IBD, asthma, COPD, and other conditions. The therapies were designed to help patients in all groups by focusing on the commonalities in inflammatory pathways that lead to significant pain and suffering across these patient populations.
Finally, the company's third patent describes the use of a myrcene-containing complex mixture for the treatment of heart disease. Despite being the number one cause of death in the U.S., there haven't been any novel formulations in nearly 20 years. The company's therapeutics target the TRPV1 receptor that is protected under the approved patent that it licensed from Makai Biotechnology as of December 2016.
GB Sciences Inc. is well-positioned to capitalize on the growing potential for cannabinoids to treat serious medical conditions. Unlike many of its competitors, the company has carefully developed an efficient process for identifying and developing therapeutic candidates across a wide range of medical conditions. These conditions share commonalities that make class-level therapeutics possible in many cases.
Please follow the link to read the full article: http://www.cannabisfn.com/gb-sciences-builds-broad-cannabis-patent-portfolio/
Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/
Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.
Source: CFN Media